Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene
Top Cited Papers
- 1 June 2003
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (11) , 6305-6313
- https://doi.org/10.1128/jvi.77.11.6305-6313.2003
Abstract
Cellular immune responses, particularly those associated with CD3+ CD8+ cytotoxic T lymphocytes (CTL), play a primary role in controlling viral infection, including persistent infection with human immunodeficiency virus type 1 (HIV-1). Accordingly, recent HIV-1 vaccine research efforts have focused on establishing the optimal means of eliciting such antiviral CTL immune responses. We evaluated several DNA vaccine formulations, a modified vaccinia virus Ankara vector, and a replication-defective adenovirus serotype 5 (Ad5) vector, each expressing the same codon-optimized HIV-1 gag gene for immunogenicity in rhesus monkeys. The DNA vaccines were formulated with and without one of two chemical adjuvants (aluminum phosphate and CRL1005). The Ad5-gag vector was the most effective in eliciting anti-Gag CTL. The vaccine produced both CD4+ and CD8+ T-cell responses, with the latter consistently being the dominant component. To determine the effect of existing antiadenovirus immunity on Ad5-gag-induced immune responses, monkeys were exposed to adenovirus subtype 5 that did not encode antigen prior to immunization with Ad5-gag. The resulting anti-Gag T-cell responses were attenuated but not abolished. Regimens that involved priming with different DNA vaccine formulations followed by boosting with the adenovirus vector were also compared. Of the formulations tested, the DNA-CRL1005 vaccine primed T-cell responses most effectively and provided the best overall immune responses after boosting with Ad5-gag. These results are suggestive of an immunization strategy for humans that are centered on use of the adenovirus vector and in which existing adenovirus immunity may be overcome by combined immunization with adjuvanted DNA and adenovirus vector boosting.Keywords
This publication has 37 references indexed in Scilit:
- Sustained Peptide-Specific Gamma Interferon T-Cell Response in Rhesus Macaques Immunized with Human Immunodeficiency Virus gag DNA VaccinesJournal of Virology, 2002
- Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunityNature, 2002
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineScience, 2001
- Evaluation of Cytotoxic T-Lymphocyte Responses in Human and Nonhuman Primate Subjects Infected with Human Immunodeficiency Virus Type 1 or Simian/Human Immunodeficiency VirusJournal of Virology, 2001
- Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA VaccinationScience, 2000
- HIV-1–Specific Cytolytic T-Lymphocyte Activity Correlates With Lower Viral Load, Higher CD4 Count, and CD8+CD38−DR− Phenotype: Comparison of Statistical Methods for MeasurementJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + LymphocytesScience, 1999
- Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal modelVaccine, 1996
- Intra- and Extracellular Immunization Against HIV-1 Infection with Lymphocytes Transduced with an AAV Vector Expressing a Human Anti-gp120 AntibodyHuman Gene Therapy, 1996
- Synthetic oligonucleotide probes deduced from amino acid sequence dataJournal of Molecular Biology, 1985